Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CD8-Positive T-Lymphocytes | 25 | 2017 | 91 | 5.540 |
Why?
|
| Immunologic Memory | 16 | 2017 | 32 | 3.070 |
Why?
|
| Lymphocytic choriomeningitis virus | 17 | 2017 | 22 | 2.960 |
Why?
|
| Lymphocytic Choriomeningitis | 15 | 2016 | 19 | 1.590 |
Why?
|
| Lymphocyte Activation | 13 | 2015 | 88 | 1.480 |
Why?
|
| Reactive Oxygen Species | 7 | 2012 | 157 | 1.420 |
Why?
|
| Mice | 32 | 2020 | 2475 | 1.210 |
Why?
|
| Rhadinovirus | 3 | 2017 | 4 | 1.210 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2015 | 57 | 1.160 |
Why?
|
| Apoptosis | 9 | 2012 | 354 | 1.060 |
Why?
|
| Animals | 35 | 2020 | 7466 | 0.930 |
Why?
|
| Arenaviridae Infections | 2 | 2014 | 2 | 0.920 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2017 | 23 | 0.910 |
Why?
|
| Photosensitizing Agents | 3 | 2020 | 24 | 0.880 |
Why?
|
| Mice, Inbred C57BL | 21 | 2019 | 766 | 0.860 |
Why?
|
| Graft vs Host Disease | 2 | 2020 | 21 | 0.860 |
Why?
|
| Apoptosis Regulatory Proteins | 4 | 2012 | 41 | 0.790 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2012 | 85 | 0.760 |
Why?
|
| Metalloporphyrins | 3 | 2012 | 16 | 0.760 |
Why?
|
| Membrane Proteins | 5 | 2019 | 257 | 0.740 |
Why?
|
| Selenium Compounds | 1 | 2020 | 1 | 0.730 |
Why?
|
| Cell Proliferation | 9 | 2014 | 599 | 0.700 |
Why?
|
| Cysteine | 2 | 2012 | 138 | 0.660 |
Why?
|
| Virus Latency | 2 | 2017 | 7 | 0.640 |
Why?
|
| T-Lymphocytes | 5 | 2020 | 124 | 0.590 |
Why?
|
| B-Lymphocytes | 3 | 2014 | 74 | 0.590 |
Why?
|
| Virus Diseases | 1 | 2017 | 22 | 0.590 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2013 | 27 | 0.560 |
Why?
|
| Autoimmunity | 5 | 2019 | 32 | 0.550 |
Why?
|
| Organogold Compounds | 1 | 2015 | 4 | 0.520 |
Why?
|
| Antioxidants | 2 | 2012 | 114 | 0.480 |
Why?
|
| Dendritic Cells | 5 | 2020 | 60 | 0.460 |
Why?
|
| Sulfhydryl Compounds | 1 | 2013 | 33 | 0.450 |
Why?
|
| Cell Membrane | 1 | 2013 | 96 | 0.450 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 13 | 0.430 |
Why?
|
| Antibodies, Viral | 1 | 2012 | 58 | 0.420 |
Why?
|
| Mice, Transgenic | 9 | 2013 | 261 | 0.410 |
Why?
|
| Mice, Knockout | 10 | 2019 | 444 | 0.400 |
Why?
|
| Peroxiredoxins | 1 | 2012 | 116 | 0.390 |
Why?
|
| Free Radical Scavengers | 2 | 2012 | 14 | 0.350 |
Why?
|
| Signal Transduction | 4 | 2014 | 687 | 0.350 |
Why?
|
| Phosphoproteins | 3 | 2019 | 51 | 0.350 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2012 | 4 | 0.320 |
Why?
|
| Gamma Rays | 2 | 2006 | 25 | 0.320 |
Why?
|
| Cell Division | 5 | 2012 | 95 | 0.310 |
Why?
|
| Cell Differentiation | 4 | 2014 | 468 | 0.310 |
Why?
|
| Exodeoxyribonucleases | 2 | 2019 | 19 | 0.300 |
Why?
|
| Cells, Cultured | 6 | 2019 | 833 | 0.290 |
Why?
|
| Electron Transport Complex I | 1 | 2006 | 4 | 0.280 |
Why?
|
| Chronic Disease | 3 | 2017 | 401 | 0.280 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2006 | 59 | 0.280 |
Why?
|
| Flow Cytometry | 5 | 2015 | 186 | 0.260 |
Why?
|
| Mitochondria | 3 | 2016 | 186 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
| Female | 11 | 2020 | 19954 | 0.230 |
Why?
|
| Up-Regulation | 2 | 2020 | 189 | 0.230 |
Why?
|
| Intracellular Membranes | 1 | 2003 | 9 | 0.220 |
Why?
|
| Cytokines | 4 | 2015 | 260 | 0.220 |
Why?
|
| Pesticides | 1 | 2016 | 200 | 0.220 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2014 | 35 | 0.220 |
Why?
|
| Organoselenium Compounds | 2 | 2016 | 3 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 233 | 0.220 |
Why?
|
| Interphase | 1 | 2002 | 1 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 291 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 245 | 0.210 |
Why?
|
| Down-Regulation | 4 | 2012 | 142 | 0.210 |
Why?
|
| Time Factors | 5 | 2012 | 2152 | 0.180 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 2 | 2012 | 7 | 0.180 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 2 | 2012 | 8 | 0.180 |
Why?
|
| Cyclohexanones | 2 | 2012 | 18 | 0.180 |
Why?
|
| Actins | 2 | 2012 | 52 | 0.180 |
Why?
|
| Leukemia | 1 | 2020 | 40 | 0.180 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 1017 | 0.180 |
Why?
|
| Apolipoprotein A-I | 2 | 2010 | 68 | 0.170 |
Why?
|
| DNA | 3 | 2019 | 228 | 0.170 |
Why?
|
| Lymphocyte Depletion | 2 | 2016 | 17 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 942 | 0.170 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2019 | 148 | 0.160 |
Why?
|
| Acute Disease | 4 | 2014 | 254 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2007 | 36 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2007 | 43 | 0.140 |
Why?
|
| Phosphorylation | 3 | 2012 | 230 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 3 | 2016 | 168 | 0.140 |
Why?
|
| Photopheresis | 1 | 2016 | 1 | 0.140 |
Why?
|
| Rhodamines | 1 | 2016 | 4 | 0.140 |
Why?
|
| Cell Survival | 2 | 2008 | 286 | 0.140 |
Why?
|
| Homeostasis | 2 | 2014 | 132 | 0.130 |
Why?
|
| Mutation | 3 | 2015 | 488 | 0.130 |
Why?
|
| Interferon-gamma | 3 | 2014 | 57 | 0.130 |
Why?
|
| Acridines | 1 | 2015 | 19 | 0.130 |
Why?
|
| Urea | 1 | 2015 | 37 | 0.130 |
Why?
|
| Platinum | 1 | 2015 | 21 | 0.130 |
Why?
|
| Chilblains | 1 | 2015 | 4 | 0.130 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2015 | 13 | 0.130 |
Why?
|
| Viral Load | 1 | 2015 | 70 | 0.130 |
Why?
|
| Phenotype | 2 | 2015 | 639 | 0.130 |
Why?
|
| Interferon-beta | 2 | 2006 | 18 | 0.130 |
Why?
|
| Herpesviridae Infections | 1 | 2014 | 6 | 0.120 |
Why?
|
| Interferon Type I | 1 | 2014 | 11 | 0.120 |
Why?
|
| Receptors, Immunologic | 1 | 2014 | 21 | 0.120 |
Why?
|
| DNA Damage | 1 | 2015 | 98 | 0.120 |
Why?
|
| Tumor Virus Infections | 1 | 2014 | 21 | 0.120 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 268 | 0.120 |
Why?
|
| Lymphoid Tissue | 1 | 2013 | 10 | 0.120 |
Why?
|
| Whole-Body Irradiation | 2 | 2006 | 50 | 0.120 |
Why?
|
| Spleen | 3 | 2014 | 86 | 0.120 |
Why?
|
| Immunophenotyping | 1 | 2013 | 51 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 629 | 0.110 |
Why?
|
| Diet, Atherogenic | 2 | 2010 | 61 | 0.110 |
Why?
|
| Calcium | 1 | 2015 | 307 | 0.110 |
Why?
|
| Cell Line | 3 | 2012 | 435 | 0.110 |
Why?
|
| Lymphopoiesis | 1 | 2012 | 4 | 0.110 |
Why?
|
| Antibody-Producing Cells | 1 | 2012 | 3 | 0.110 |
Why?
|
| Cytoprotection | 1 | 2012 | 6 | 0.110 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2012 | 11 | 0.110 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2012 | 50 | 0.110 |
Why?
|
| Cricetinae | 2 | 2012 | 39 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 20 | 0.110 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2012 | 25 | 0.100 |
Why?
|
| Biological Transport | 1 | 2012 | 69 | 0.100 |
Why?
|
| Vaccinia virus | 1 | 2012 | 14 | 0.100 |
Why?
|
| Diacylglycerol Kinase | 1 | 2012 | 2 | 0.100 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 121 | 0.100 |
Why?
|
| Blotting, Western | 1 | 2012 | 292 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2012 | 78 | 0.100 |
Why?
|
| Antigens, Viral | 1 | 2011 | 21 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2014 | 211 | 0.100 |
Why?
|
| Humans | 9 | 2019 | 32025 | 0.100 |
Why?
|
| Inflammation | 1 | 2015 | 540 | 0.100 |
Why?
|
| Adoptive Transfer | 3 | 2012 | 26 | 0.100 |
Why?
|
| Antigens | 2 | 2007 | 31 | 0.090 |
Why?
|
| Listeria monocytogenes | 1 | 2010 | 9 | 0.090 |
Why?
|
| Interleukin-12 | 1 | 2010 | 29 | 0.090 |
Why?
|
| Interleukin-23 | 1 | 2010 | 21 | 0.090 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2009 | 65 | 0.080 |
Why?
|
| Azoles | 1 | 2008 | 2 | 0.080 |
Why?
|
| Sulfhydryl Reagents | 1 | 2008 | 6 | 0.080 |
Why?
|
| Ethylmaleimide | 1 | 2008 | 6 | 0.080 |
Why?
|
| Virulence | 1 | 2008 | 22 | 0.080 |
Why?
|
| Macrophages, Peritoneal | 1 | 2008 | 18 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2009 | 108 | 0.080 |
Why?
|
| Aortic Diseases | 1 | 2009 | 63 | 0.080 |
Why?
|
| Lymphatic Diseases | 1 | 2008 | 10 | 0.080 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 52 | 0.080 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2007 | 17 | 0.080 |
Why?
|
| Sulfinic Acids | 1 | 2007 | 13 | 0.080 |
Why?
|
| Cholesterol | 1 | 2009 | 251 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 470 | 0.070 |
Why?
|
| Rotenone | 1 | 2006 | 3 | 0.070 |
Why?
|
| Ionomycin | 1 | 2006 | 4 | 0.070 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2006 | 11 | 0.070 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2006 | 9 | 0.070 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 9 | 0.070 |
Why?
|
| Lymph Nodes | 3 | 2014 | 106 | 0.070 |
Why?
|
| Lymphocyte Count | 3 | 2014 | 24 | 0.070 |
Why?
|
| Membrane Potentials | 2 | 2003 | 81 | 0.070 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 6 | 0.070 |
Why?
|
| STAT3 Transcription Factor | 1 | 2006 | 25 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 40 | 0.070 |
Why?
|
| Cell Count | 1 | 2006 | 47 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2006 | 103 | 0.070 |
Why?
|
| Peptides | 1 | 2006 | 119 | 0.070 |
Why?
|
| Kidney | 1 | 2009 | 515 | 0.060 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 9 | 0.060 |
Why?
|
| Viral Structural Proteins | 1 | 2003 | 7 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 147 | 0.060 |
Why?
|
| Viral Proteins | 1 | 2003 | 35 | 0.060 |
Why?
|
| Interferon-alpha | 2 | 2019 | 70 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2016 | 897 | 0.060 |
Why?
|
| Caspases | 1 | 2003 | 38 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2004 | 180 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2003 | 30 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2003 | 135 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 208 | 0.050 |
Why?
|
| Immunization, Secondary | 1 | 2002 | 11 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 76 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2009 | 767 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1516 | 0.050 |
Why?
|
| Male | 5 | 2016 | 19196 | 0.050 |
Why?
|
| Nucleotidyltransferases | 1 | 2019 | 8 | 0.040 |
Why?
|
| Autoantigens | 1 | 2019 | 16 | 0.040 |
Why?
|
| Receptors, LDL | 2 | 2010 | 65 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2019 | 74 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2016 | 25 | 0.030 |
Why?
|
| Verapamil | 1 | 2016 | 8 | 0.030 |
Why?
|
| Light | 1 | 2016 | 24 | 0.030 |
Why?
|
| Macrophages | 2 | 2010 | 192 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 151 | 0.030 |
Why?
|
| Lymphoma | 1 | 2016 | 35 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2016 | 148 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2015 | 48 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 40 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 52 | 0.030 |
Why?
|
| Base Sequence | 1 | 2015 | 251 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 8 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 356 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 248 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 27 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 24 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 725 | 0.030 |
Why?
|
| RNA Caps | 1 | 2012 | 1 | 0.030 |
Why?
|
| Natural Killer T-Cells | 1 | 2012 | 2 | 0.030 |
Why?
|
| Ovalbumin | 1 | 2012 | 3 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2012 | 2 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2012 | 18 | 0.030 |
Why?
|
| Purines | 1 | 2012 | 22 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2012 | 26 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 61 | 0.030 |
Why?
|
| Adult | 1 | 2016 | 9367 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2012 | 6 | 0.030 |
Why?
|
| Aged | 1 | 2016 | 10340 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2012 | 12 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2012 | 108 | 0.030 |
Why?
|
| Clone Cells | 1 | 2012 | 36 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2012 | 24 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2012 | 45 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 155 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2012 | 80 | 0.020 |
Why?
|
| Middle Aged | 1 | 2016 | 11868 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2012 | 108 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2010 | 35 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 88 | 0.020 |
Why?
|
| Immunotherapy, Active | 1 | 2010 | 6 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 20 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 177 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 398 | 0.020 |
Why?
|
| Maleimides | 1 | 2009 | 5 | 0.020 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2009 | 2 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2009 | 31 | 0.020 |
Why?
|
| Losartan | 1 | 2009 | 64 | 0.020 |
Why?
|
| Lipids | 1 | 2010 | 229 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2009 | 117 | 0.020 |
Why?
|
| Indoles | 1 | 2009 | 56 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 65 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2009 | 81 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2009 | 49 | 0.020 |
Why?
|
| Skin | 1 | 2010 | 210 | 0.020 |
Why?
|
| Aorta | 1 | 2009 | 125 | 0.020 |
Why?
|
| Genital Diseases, Female | 1 | 2007 | 5 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 90 | 0.020 |
Why?
|
| TYK2 Kinase | 1 | 2006 | 1 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2006 | 8 | 0.020 |
Why?
|
| Interleukin-7 | 1 | 2006 | 11 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2006 | 51 | 0.020 |
Why?
|
| Tyrosine | 1 | 2006 | 23 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2006 | 29 | 0.020 |
Why?
|
| Rats | 1 | 2009 | 1596 | 0.020 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2004 | 4 | 0.020 |
Why?
|
| Pregnancy | 1 | 2007 | 994 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2003 | 4 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 42 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2003 | 68 | 0.010 |
Why?
|